A Phase 3 randomised study to evaluate the safety and antiviral activity of Remdesivir (GS-5734™) in participants with severe COVID-19 compared to standard of care treatment
Site and lead:
- Manchester Royal Infirmary: Dr Shazaad Ahmed
Patient group: COVID-19 patients in hospital
Funder: Gilead Sciences Inc
Sponsor: Gilead Sciences Inc
More about the GS-5773 study
- GS-5773 is a nationally-prioritised COVID-19 study. See the full list Urgent Public Health COVID-19 Studies on the NIHR website.
The primary purpose of this study is to evaluate the efficacy of two remdesivir (RDV) regimens with respect to the normalisation of temperature and oxygen saturation through Day 14 in participants with severe coronavirus disease (COVID-19).